Literature DB >> 17618301

Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro.

F P Leung1, L M Yung, H S Leung, C L Au, X Yao, P M Vanhoutte, I Laher, Y Huang.   

Abstract

BACKGROUND AND
PURPOSE: Raloxifene improves cardiovascular function. This study examines the hypothesis that therapeutic concentrations of raloxifene augment endothelium-dependent relaxation via up-regulation of eNOS expression and activity in porcine coronary arteries. EXPERIMENTAL APPROACH: Isometric tension was measured in rings from isolated arteries. Intracellular Ca(2+) concentrations ([Ca(2+)](i)) in arterial endothelial cells were detected by Ca(2+) fluorescence imaging. Phosphorylation of eNOS at Ser-1177 was assayed by Western blot analysis. KEY
RESULTS: In arterial rings pre-contracted with 9,11-dideoxy-11alpha,9alpha-epoxy-methano-prostaglandin F(2alpha) (U46619), treatment with raloxifene (1-3 nM) augmented bradykinin- or substance P-induced relaxation and this effect was antagonized by ICI 182,780, an estrogen receptor antagonist. The enhanced relaxation was abolished in rings treated with inhibitors of nitric oxide/cyclic GMP-dependent dilation, N(G)-nitro-L-arginine methyl ester (L-NAME) plus 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ). In contrast, effects of raloxifene were unaffected after inhibition of endothelium-derived hyperpolarizing factors by charybdotoxin plus apamin. Raloxifene (3 nM) did not influence endothelium-independent relaxation to sodium nitroprusside. 17beta-Estradiol (3-10 nM) also enhanced bradykinin-induced relaxation, which was inhibited by ICI 182,780. Treatment with raloxifene (3 nM) did not affect bradykinin-stimulated rise in endothelial cell [Ca(2+)](i). Raloxifene, 17beta-estradiol, and bradykinin increased eNOS phosphorylation at Ser-1177 and ICI 182,780 prevented effects of raloxifene or 17beta-estradiol but not that of bradykinin. Raloxifene had neither additive nor antagonistic effects on 17beta-estradiol-induced eNOS phosphorylation. CONCLUSIONS AND IMPLICATIONS: Raloxifene in therapeutically relevant concentrations augmented endothelial function in porcine coronary arteries in vitro through ICI 182,780-sensitive mechanisms that were associated with increased phosphorylation of eNOS but independent of changes in endothelial cell [Ca(2+)](i).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17618301      PMCID: PMC1978259          DOI: 10.1038/sj.bjp.0707387

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Isoproterenol amplifies 17 beta-estradiol-mediated vasorelaxation: role of endothelium/nitric oxide and cyclic AMP.

Authors:  Hoi Yun Chan; Xiaoqiang Yao; Suk Ying Tsang; Jean-Pierre Bourreau; Franky Leung Chan; Yu Huang
Journal:  Cardiovasc Res       Date:  2002-02-15       Impact factor: 10.787

2.  Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

Authors:  Elizabeth Barrett-Connor; Deborah Grady; Andreas Sashegyi; Pamela W Anderson; David A Cox; Krzysztof Hoszowski; Pentti Rautaharju; Kristine D Harper
Journal:  JAMA       Date:  2002-02-20       Impact factor: 56.272

3.  Raloxifene and endothelial function in healthy postmenopausal women.

Authors:  Philip M Sarrel; Haq Nawaz; Wendy Chan; Melissa Fuchs; David L Katz
Journal:  Am J Obstet Gynecol       Date:  2003-02       Impact factor: 8.661

Review 4.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease.

Authors:  Kaye A Griffiths; Mark A Sader; Michael R Skilton; Jason A Harmer; David S Celermajer
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

6.  Endothelial function and menopause: effects of raloxifene administration.

Authors:  Nicola Colacurci; Daniela Manzella; Felice Fornaro; Marco Carbonella; Giuseppe Paolisso
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

7.  Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice.

Authors:  Hisakazu Ogita; Koichi Node; Yulin Liao; Fuminobu Ishikura; Shintaro Beppu; Hiroshi Asanuma; Shoji Sanada; Seiji Takashima; Tetsuo Minamino; Masatsugu Hori; Masafumi Kitakaze
Journal:  Hypertension       Date:  2003-12-15       Impact factor: 10.190

Review 8.  From nitric oxide to endothelial cytosolic Ca2+: a negative feedback control.

Authors:  Xiaoqiang Yao; Yu Huang
Journal:  Trends Pharmacol Sci       Date:  2003-06       Impact factor: 14.819

9.  The effects of raloxifene and simvastatin on plasma lipids and endothelium.

Authors:  Eftihia Sbarouni; Panagiota Flevari; Christos Kroupis; Zenon S Kyriakides; Katerina Koniavitou; Dimitrios Th Kremastinos
Journal:  Cardiovasc Drugs Ther       Date:  2003-07       Impact factor: 3.727

10.  Different role of nitric oxide and endothelium-derived hyperpolarizing factor in endothelium-dependent hyperpolarization and relaxation in porcine coronary arterial and venous system.

Authors:  Rong-Zhen Zhang; Qin Yang; Anthony P C Yim; Yu Huang; Guo-Wei He
Journal:  J Cardiovasc Pharmacol       Date:  2004-06       Impact factor: 3.105

View more
  6 in total

Review 1.  The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Vascul Pharmacol       Date:  2011-07-05       Impact factor: 5.773

2.  GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure.

Authors:  Matthias R Meyer; Eric R Prossnitz; Matthias Barton
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2011

3.  Raloxifene protects endothelial cell function against oxidative stress.

Authors:  C M Wong; L M Yung; F P Leung; S-Y Tsang; C L Au; Z-Y Chen; X Yao; C H K Cheng; C-W Lau; M Gollasch; Y Huang
Journal:  Br J Pharmacol       Date:  2008-06-23       Impact factor: 8.739

4.  Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice.

Authors:  F Moien-Afshari; S Ghosh; S Elmi; M M Rahman; N Sallam; M Khazaei; T J Kieffer; R W Brownsey; I Laher
Journal:  Diabetologia       Date:  2008-04-25       Impact factor: 10.122

Review 5.  Membrane-initiated actions of estrogen on the endothelium.

Authors:  Kyung Hee Kim; Jeffrey R Bender
Journal:  Mol Cell Endocrinol       Date:  2009-04-09       Impact factor: 4.102

6.  Calycosin promotes angiogenesis involving estrogen receptor and mitogen-activated protein kinase (MAPK) signaling pathway in zebrafish and HUVEC.

Authors:  Jing Yan Tang; Shang Li; Zhen Hua Li; Zai Jun Zhang; Guang Hu; Lorita Chi Veng Cheang; Deepa Alex; Maggie Pui Man Hoi; Yiu Wa Kwan; Shun Wan Chan; George Pak Heng Leung; Simon Ming Yuen Lee
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.